NK CellTech closes Series A to raise over $15M; Triastek
Elise Mak ·07/01/2022

Top news story of the day:


NK CellTech closes Series A to raise over $15M


Shanghai startup NK CellTech closed a Series A round to raise over RMB100 million ($15 million) to help it advance its NK cell therapy pipeline and R&D. The financing round was led by Huagai Capital.


The biotech firm was founded by Tian Zhigang, Chief of Supervisory Board at Chinese Society of Immunology as well as Director, Institute of Immunology. Little is known about NK CellTech now, as it has not disclosed its pipeline. It said it uses synthetic immunology technology to enable the development of quantitative and controllable NK cell drugs through gene operations to create NK cells that meet different clinical needs.


In a paper co-authored by Tian, researchers said advances in synthetic biology and the development of novel genetic engineering techniques, such as gene-editing and cellular reprogramming, will enable the further optimization of innate killer cells (IKC)-based anticancer therapies. IKCs are associated with a low risk of developing GVHD, thus offering new opportunities for allogeneic “off-the-shelf” cellular therapeutic products. 



By Elise Mak


What else in China:


Triastek's first 3D printed drug product for rheumatoid arthritis, T19, receives IND approval in China.


By Sarina Yang

Keywords: NK CellTech Triastek
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback: Support@PharmaDJ.com   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement